{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:08:55Z","timestamp":1792458535239,"version":"4.5.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11657-020-00819-z","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T18:02:27Z","timestamp":1600106547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of iron overload on bone remodeling in thalassemia"],"prefix":"10.1007","volume":"15","author":[{"given":"Pokpong","family":"Piriyakhuntorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adisak","family":"Tantiworawit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattabhorn","family":"Phimphilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krekwit","family":"Shinlapawittayatorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriporn C.","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipon","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"issue":"1","key":"819_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.24330","volume":"54","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS (2011) American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 54(1):328\u2013343","journal-title":"Hepatology."},{"issue":"12 Suppl","key":"819_CR2","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ajh.21075","volume":"82","author":"GJ Anderson","year":"2007","unstructured":"Anderson GJ (2007) Mechanisms of iron loading and toxicity. Am J Hematol 82(12 Suppl):1128\u20131131","journal-title":"Am J Hematol"},{"issue":"4","key":"819_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00198-008-0701-4","volume":"20","author":"L Valenti","year":"2009","unstructured":"Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L (2009) Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20(4):549\u2013555","journal-title":"Osteoporos Int"},{"key":"819_CR4","doi-asserted-by":"publisher","unstructured":"(1993) Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646\u2013650.\u00a0https:\/\/doi.org\/10.1016\/0002-9343(93)90218-e","DOI":"10.1016\/0002-9343(93)90218-e"},{"issue":"2","key":"819_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2141.2004.05143.x","volume":"127","author":"E Voskaridou","year":"2004","unstructured":"Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127(2):127\u2013139","journal-title":"Br J Haematol"},{"issue":"2","key":"819_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4274\/jcrpe.galenos.2018.2018.0074","volume":"11","author":"A Gaudio","year":"2019","unstructured":"Gaudio A, Morabito N, Catalano A, Rapisarda R, Xourafa A, Lasco A (2019) Pathogenesis of thalassemia major-associated osteoporosis: a review with insights from clinical experience. J Clin Res Pediatr Endocrinol 11(2):110\u2013117","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"3","key":"819_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bone.2010.10.173","volume":"48","author":"R Haidar","year":"2011","unstructured":"Haidar R, Musallam KM, Taher AT (2011) Bone disease and skeletal complications in patients with beta thalassemia major. Bone. 48(3):425\u2013432","journal-title":"Bone."},{"issue":"4","key":"819_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/er.2015-1105","volume":"37","author":"P Wong","year":"2016","unstructured":"Wong P, Fuller PJ, Gillespie MT, Milat F (2016) Bone disease in thalassemia: a molecular and clinical overview. Endocr Rev 37(4):320\u2013346","journal-title":"Endocr Rev"},{"issue":"2\u20133","key":"819_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bcmd.2013.09.008","volume":"52","author":"M Baldini","year":"2014","unstructured":"Baldini M, Forti S, Orsatti A, Marcon A, Ulivieri FM, Airaghi L et al (2014) Thalassemic osteopathy: a new marker of bone deposition. Blood Cells Mol Dis 52(2\u20133):91\u201394","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"819_CR10","first-page":"1425","volume":"28","author":"U Dundar","year":"2007","unstructured":"Dundar U, Kupesiz A, Ozdem S, Gilgil E, Tuncer T, Yesilipek A, Gultekin M (2007) Bone metabolism and mineral density in patients with beta-thalassemia major. Saudi Med J 28(9):1425\u20131429","journal-title":"Saudi Med J"},{"issue":"1","key":"819_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1742-1241.2005.00358.x","volume":"59","author":"E Eren","year":"2005","unstructured":"Eren E, Yilmaz N (2005) Biochemical markers of bone turnover and bone mineral density in patients with beta-thalassaemia major. Int J Clin Pract 59(1):46\u201351","journal-title":"Int J Clin Pract"},{"issue":"6","key":"819_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.bone.2011.03.765","volume":"48","author":"EB Fung","year":"2011","unstructured":"Fung EB, Vichinsky EP, Kwiatkowski JL, Huang J, Bachrach LK, Sawyer AJ, Zemel BS (2011) Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone. 48(6):1305\u20131312","journal-title":"Bone."},{"issue":"Suppl 1","key":"819_CR13","first-page":"116","volume":"6","author":"A Kyriakou","year":"2008","unstructured":"Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S et al (2008) Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev 6(Suppl 1):116\u2013122","journal-title":"Pediatr Endocrinol Rev"},{"issue":"6","key":"819_CR14","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.bone.2007.02.020","volume":"40","author":"N Morabito","year":"2007","unstructured":"Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, Franchina F, Maisano D, la Rosa M, Plota M, Crif\u00f2 A, Meo A, Frisina N (2007) The \u201clively\u201d cytokines network in beta-thalassemia major-related osteoporosis. Bone. 40(6):1588\u20131594","journal-title":"Bone."},{"issue":"1","key":"819_CR15","first-page":"17","volume":"51","author":"AC Pietrapertosa","year":"2009","unstructured":"Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M (2009) Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. Panminerva Med 51(1):17\u201323","journal-title":"Panminerva Med"},{"issue":"2","key":"819_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12020-016-0865-1","volume":"53","author":"M Scacchi","year":"2016","unstructured":"Scacchi M, Danesi L, Cattaneo A, Sciortino G, Radin R, Ambrogio AG, Vitale G, D'Angelo E, Mirra N, Zanaboni L, Arvigo M, Boschetti M, Ferone D, Marzullo P, Baldini M, Cassinerio E, Cappellini MD, Persani L, Cavagnini F (2016) Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. Endocrine. 53(2):551\u2013557","journal-title":"Endocrine."},{"issue":"3","key":"819_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1359\/jbmr.080505","volume":"24","author":"MG Vogiatzi","year":"2009","unstructured":"Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ, Thalassemia Clinical Research Network (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543\u2013557","journal-title":"J Bone Miner Res"},{"key":"819_CR18","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","volume":"37","author":"FT Shah","year":"2019","unstructured":"Shah FT, Sayani F, Trompeter S, Drasar E, Piga A (2019) Challenges of blood transfusions in beta-thalassemia. Blood Rev 37:100588","journal-title":"Blood Rev"},{"issue":"12","key":"819_CR19","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/blood-2011-04-344507","volume":"119","author":"JL Kwiatkowski","year":"2012","unstructured":"Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I et al (2012) Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 119(12):2746\u20132753","journal-title":"Blood."},{"issue":"4","key":"819_CR20","first-page":"328","volume":"8","author":"AK Mishra","year":"2013","unstructured":"Mishra AK, Tiwari A (2013) Iron overload in beta thalassaemia major and intermedia patients. Maedica (Buchar) 8(4):328\u2013332","journal-title":"Maedica (Buchar)"},{"issue":"3","key":"819_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1042\/BJ20101825","volume":"434","author":"J Wang","year":"2011","unstructured":"Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J 434(3):365\u2013381","journal-title":"Biochem J"},{"issue":"3","key":"819_CR22","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1210\/endo-126-3-1742","volume":"126","author":"K Kasai","year":"1990","unstructured":"Kasai K, Hori MT, Goodman WG (1990) Characterization of the transferrin receptor in UMR-106-01 osteoblast-like cells. Endocrinology. 126(3):1742\u20131749","journal-title":"Endocrinology."},{"issue":"3","key":"819_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7150\/ijms.17860","volume":"14","author":"F Liu","year":"2017","unstructured":"Liu F, Zhang WL, Meng HZ, Cai ZY, Yang MW (2017) Regulation of DMT1 on autophagy and apoptosis in osteoblast. Int J Med Sci 14(3):275\u2013283","journal-title":"Int J Med Sci"},{"issue":"10","key":"819_CR24","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24(10):R453\u2013R462","journal-title":"Curr Biol"},{"issue":"9","key":"819_CR25","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.bbadis.2016.06.003","volume":"1862","author":"E Balogh","year":"2016","unstructured":"Balogh E, Tolnai E, Nagy B Jr, Nagy B, Balla G, Balla J et al (2016) Iron overload inhibits osteogenic commitment and differentiation of mesenchymal stem cells via the induction of ferritin. Biochim Biophys Acta 1862(9):1640\u20131649","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"819_CR26","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s00198-011-1871-z","volume":"23","author":"M Doyard","year":"2012","unstructured":"Doyard M, Fatih N, Monnier A, Island ML, Aubry M, Leroyer P, Bouvet R, Chal\u00e8s G, Mosser J, Lor\u00e9al O, Guggenbuhl P (2012) Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells. Osteoporos Int 23(10):2435\u20132445","journal-title":"Osteoporos Int"},{"issue":"2","key":"819_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12011-013-9605-z","volume":"152","author":"YF He","year":"2013","unstructured":"He YF, Ma Y, Gao C, Zhao GY, Zhang LL, Li GF et al (2013) Iron overload inhibits osteoblast biological activity through oxidative stress. Biol Trace Elem Res 152(2):292\u2013296","journal-title":"Biol Trace Elem Res"},{"issue":"6","key":"819_CR28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/odi.12662","volume":"23","author":"JY Ke","year":"2017","unstructured":"Ke JY, Cen WJ, Zhou XZ, Li YR, Kong WD, Jiang JW (2017) Iron overload induces apoptosis of murine preosteoblast cells via ROS and inhibition of AKT pathway. Oral Dis 23(6):784\u2013794","journal-title":"Oral Dis"},{"key":"819_CR29","doi-asserted-by":"publisher","first-page":"e2611","DOI":"10.7717\/peerj.2611","volume":"4","author":"Q Tian","year":"2016","unstructured":"Tian Q, Wu S, Dai Z, Yang J, Zheng J, Zheng Q et al (2016) Iron overload induced death of osteoblasts in vitro: involvement of the mitochondrial apoptotic pathway. PeerJ. 4:e2611","journal-title":"PeerJ."},{"key":"819_CR30","doi-asserted-by":"publisher","first-page":"15668","DOI":"10.1002\/jcp.28217","volume":"234","author":"D Xia","year":"2019","unstructured":"Xia D, Wu J, Xing M, Wang Y, Zhang H, Xia Y, Zhou P, Xu S (2019) Iron overload threatens the growth of osteoblast cells via inhibiting the PI3K\/AKT\/FOXO3a\/DUSP14 signaling pathway. J Cell Physiol 234:15668\u201315677","journal-title":"J Cell Physiol"},{"issue":"4","key":"819_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1530\/JME-17-0301","volume":"60","author":"P Zhang","year":"2018","unstructured":"Zhang P, Wang S, Wang L, Shan BC, Zhang H, Yang F, Zhou ZQ, Wang X, Yuan Y, Xu YJ (2018) Hepcidin is an endogenous protective factor for osteoporosis by reducing iron levels. J Mol Endocrinol 60(4):297\u2013306","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"819_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1530\/JOE-14-0657","volume":"226","author":"W Xiao","year":"2015","unstructured":"Xiao W, Beibei F, Guangsi S, Yu J, Wen Z, Xi H, Youjia X (2015) Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. J Endocrinol 226(3):121\u2013134","journal-title":"J Endocrinol"},{"issue":"9","key":"819_CR33","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1371\/journal.pone.0000837","volume":"2","author":"F Kugimiya","year":"2007","unstructured":"Kugimiya F, Kawaguchi H, Ohba S, Kawamura N, Hirata M, Chikuda H, Azuma Y, Woodgett JR, Nakamura K, Chung UI (2007) GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One 2(9):e837","journal-title":"PLoS One"},{"issue":"1\u20132","key":"819_CR34","first-page":"1","volume":"77","author":"S Krishan","year":"2015","unstructured":"Krishan S, Jansson PJ, Gutierrez E, Lane DJ, Richardson D, Sahni S (2015) Iron metabolism and autophagy: a poorly explored relationship that has important consequences for health and disease. Nagoya J Med Sci 77(1\u20132):1\u20136","journal-title":"Nagoya J Med Sci"},{"issue":"9","key":"819_CR35","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1002\/jcp.26405","volume":"233","author":"WJ Cen","year":"2018","unstructured":"Cen WJ, Feng Y, Li SS, Huang LW, Zhang T, Zhang W, Kong WD, Jiang JW (2018) Iron overload induces G1 phase arrest and autophagy in murine preosteoblast cells. J Cell Physiol 233(9):6779\u20136789","journal-title":"J Cell Physiol"},{"key":"819_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bone.2018.12.019","volume":"121","author":"J Wu","year":"2019","unstructured":"Wu J, Wang A, Wang X, Li G, Jia P, Shen G et al (2019) Rapamycin improves bone mass in high-turnover osteoporosis with iron accumulation through positive effects on osteogenesis and angiogenesis. Bone. 121:16\u201328","journal-title":"Bone."},{"issue":"2","key":"819_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cmet.2010.01.001","volume":"11","author":"MT Rached","year":"2010","unstructured":"Rached MT, Kode A, Xu L, Yoshikawa Y, Paik JH, Depinho RA, Kousteni S (2010) FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 11(2):147\u2013160","journal-title":"Cell Metab"},{"issue":"11","key":"819_CR38","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jnutbio.2015.05.009","volume":"26","author":"L Zhao","year":"2015","unstructured":"Zhao L, Wang Y, Wang Z, Xu Z, Zhang Q, Yin M (2015) Effects of dietary resveratrol on excess-iron-induced bone loss via antioxidative character. J Nutr Biochem 26(11):1174\u20131182","journal-title":"J Nutr Biochem"},{"issue":"1","key":"819_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"M Maceyka","year":"2012","unstructured":"Maceyka M, Harikumar KB, Milstien S, Spiegel S (2012) Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22(1):50\u201360","journal-title":"Trends Cell Biol"},{"issue":"8","key":"819_CR40","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00198-018-4531-8","volume":"29","author":"L Peltier","year":"2018","unstructured":"Peltier L, Bendavid C, Cavey T, Island ML, Doyard M, Leroyer P, Allain C, de Tayrac M, Ropert M, Lor\u00e9al O, Guggenbuhl P (2018) Iron excess upregulates SPNS2 mRNA levels but reduces sphingosine-1-phosphate export in human osteoblastic MG-63 cells. Osteoporos Int 29(8):1905\u20131915","journal-title":"Osteoporos Int"},{"issue":"2","key":"819_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/ijos.2015.14","volume":"7","author":"J Yang","year":"2015","unstructured":"Yang J, Andre P, Ye L, Yang YZ (2015) The hedgehog signalling pathway in bone formation. Int J Oral Sci 7(2):73\u201379","journal-title":"Int J Oral Sci"},{"issue":"5","key":"819_CR42","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.devcel.2008.02.003","volume":"14","author":"KK Mak","year":"2008","unstructured":"Mak KK, Bi Y, Wan C, Chuang PT, Clemens T, Young M, Yang Y (2008) Hedgehog signaling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression. Dev Cell 14(5):674\u2013688","journal-title":"Dev Cell"},{"issue":"2\u20133","key":"819_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.toxlet.2009.08.023","volume":"191","author":"K Yamasaki","year":"2009","unstructured":"Yamasaki K, Hagiwara H (2009) Excess iron inhibits osteoblast metabolism. Toxicol Lett 191(2\u20133):211\u2013215","journal-title":"Toxicol Lett"},{"issue":"5","key":"819_CR44","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.bone.2009.07.073","volume":"45","author":"JG Messer","year":"2009","unstructured":"Messer JG, Kilbarger AK, Erikson KM, Kipp DE (2009) Iron overload alters iron-regulatory genes and proteins, down-regulates osteoblastic phenotype, and is associated with apoptosis in fetal rat calvaria cultures. Bone. 45(5):972\u2013979","journal-title":"Bone."},{"issue":"12","key":"819_CR45","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3324\/haematol.2016.144808","volume":"101","author":"U Baschant","year":"2016","unstructured":"Baschant U, Rauner M, Balaian E, Weidner H, Roetto A, Platzbecker U et al (2016) Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. Haematologica. 101(12):1499\u20131507","journal-title":"Haematologica."},{"issue":"1","key":"819_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1359\/jbmr.091002","volume":"25","author":"A Zarjou","year":"2010","unstructured":"Zarjou A, Jeney V, Arosio P, Poli M, Zavaczki E, Balla G et al (2010) Ferritin ferroxidase activity: a potent inhibitor of osteogenesis. J Bone Miner Res 25(1):164\u2013172","journal-title":"J Bone Miner Res"},{"key":"819_CR47","doi-asserted-by":"publisher","unstructured":"Yang F, Yang L, Li Y, Yan G, Feng C, Liu T, Gong R, Yuan Y, Wang N, Idiiatullina E, Bikkuzin T, Pavlov V, Li Y, Dong C, Wang D, Cao Y, Han Z, Zhang L, Huang Q, Ding F, Bi Z, Cai B (2017) Melatonin protects bone marrow mesenchymal stem cells against iron overload\u2010induced aberrant differentiation and senescence. J Pineal Res\u00a063:e12422. https:\/\/doi.org\/10.1111\/jpi.12422","DOI":"10.1111\/jpi.12422"},{"key":"819_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.metabol.2018.01.005","volume":"83","author":"X Wang","year":"2018","unstructured":"Wang X, Chen B, Sun J, Jiang Y, Zhang H, Zhang P, Fei B, Xu Y (2018) Iron-induced oxidative stress stimulates osteoclast differentiation via NF-kappaB signaling pathway in mouse model. Metabolism. 83:167\u2013176","journal-title":"Metabolism."},{"key":"819_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/B978-0-12-415784-2.00002-6","volume-title":"Translational endocrinology of bone","author":"TJ Martin","year":"2013","unstructured":"Martin TJ, Wah Ng K, Sims NA (2013) Chapter 2 - Basic principles of bone cell biology. In: Karsenty G (ed) Translational endocrinology of bone. Academic Press, San Diego, pp 5\u201326"},{"issue":"2","key":"819_CR50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93(2):165\u2013176","journal-title":"Cell."},{"issue":"2","key":"819_CR51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89(2):309\u2013319","journal-title":"Cell."},{"issue":"2","key":"819_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","volume":"473","author":"BF Boyce","year":"2008","unstructured":"Boyce BF, Xing L (2008) Functions of RANKL\/RANK\/OPG in bone modeling and remodeling. Arch Biochem Biophys 473(2):139\u2013146","journal-title":"Arch Biochem Biophys"},{"issue":"6","key":"819_CR53","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"3","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3(6):889\u2013901","journal-title":"Dev Cell"},{"issue":"5","key":"819_CR54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.biocel.2009.12.018","volume":"42","author":"Q Zhao","year":"2010","unstructured":"Zhao Q, Wang X, Liu Y, He A, Jia R (2010) NFATc1: functions in osteoclasts. Int J Biochem Cell Biol 42(5):576\u2013579","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"819_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.11005\/jbm.2014.21.4.233","volume":"21","author":"JH Kim","year":"2014","unstructured":"Kim JH, Kim N (2014) Regulation of NFATc1 in osteoclast differentiation. J Bone Metab 21(4):233\u2013241","journal-title":"J Bone Metab"},{"issue":"3","key":"819_CR56","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nm.1910","volume":"15","author":"KA Ishii","year":"2009","unstructured":"Ishii KA, Fumoto T, Iwai K, Takeshita S, Ito M, Shimohata N, Aburatani H, Taketani S, Lelliott CJ, Vidal-Puig A, Ikeda K (2009) Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 15(3):259\u2013266","journal-title":"Nat Med"},{"issue":"42","key":"819_CR57","doi-asserted-by":"publisher","first-page":"30064","DOI":"10.1074\/jbc.M113.478750","volume":"288","author":"J Zhou","year":"2013","unstructured":"Zhou J, Ye S, Fujiwara T, Manolagas SC, Zhao H (2013) Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron\/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation. J Biol Chem 288(42):30064\u201330074","journal-title":"J Biol Chem"},{"key":"819_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.toxlet.2019.06.007","volume":"313","author":"J Zhang","year":"2019","unstructured":"Zhang J, Hu W, Ding C, Yao G, Zhao H, Wu S (2019) Deferoxamine inhibits iron-uptake stimulated osteoclast differentiation by suppressing electron transport chain and MAPKs signaling. Toxicol Lett 313:50\u201359","journal-title":"Toxicol Lett"},{"issue":"2","key":"819_CR59","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s10753-014-9982-2","volume":"38","author":"GY Zhao","year":"2015","unstructured":"Zhao GY, Di DH, Wang B, Huang X, Xu YJ (2015) Effects of mouse hepcidin 1 treatment on osteoclast differentiation and intracellular iron concentration. Inflammation. 38(2):718\u2013727","journal-title":"Inflammation."},{"issue":"14","key":"819_CR60","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1182\/blood-2009-12-260083","volume":"116","author":"J Tsay","year":"2010","unstructured":"Tsay J, Yang Z, Ross FP, Cunningham-Rundles S, Lin H, Coleman R et al (2010) Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood. 116(14):2582\u20132589","journal-title":"Blood."},{"issue":"11","key":"819_CR61","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/jor.22133","volume":"30","author":"P Jia","year":"2012","unstructured":"Jia P, Xu YJ, Zhang ZL, Li K, Li B, Zhang W, Yang H (2012) Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. J Orthop Res 30(11):1843\u20131852","journal-title":"J Orthop Res"},{"key":"819_CR62","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0378-4274(95)03532-X","volume":"82\u201383","author":"CC Winterbourn","year":"1995","unstructured":"Winterbourn CC (1995) Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett 82\u201383:969\u2013974","journal-title":"Toxicol Lett"},{"issue":"24","key":"819_CR63","doi-asserted-by":"publisher","first-page":"9248","DOI":"10.1074\/jbc.RA117.000834","volume":"293","author":"L Wang","year":"2018","unstructured":"Wang L, Fang B, Fujiwara T, Krager K, Gorantla A, Li C, Feng JQ, Jennings ML, Zhou J, Aykin-Burns N, Zhao H (2018) Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo. J Biol Chem 293(24):9248\u20139264","journal-title":"J Biol Chem"},{"issue":"12","key":"819_CR64","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3324\/haematol.2014.104463","volume":"99","author":"F Rossi","year":"2014","unstructured":"Rossi F, Perrotta S, Bellini G, Luongo L, Tortora C, Siniscalco D et al (2014) Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica. 99(12):1876\u20131884","journal-title":"Haematologica."},{"issue":"12","key":"819_CR65","doi-asserted-by":"publisher","first-page":"e0208102","DOI":"10.1371\/journal.pone.0208102","volume":"13","author":"F Punzo","year":"2018","unstructured":"Punzo F, Tortora C, Argenziano M, Casale M, Perrotta S, Rossi F (2018) Iron chelating properties of eltrombopag: investigating its role in thalassemia-induced osteoporosis. PLoS One 13(12):e0208102","journal-title":"PLoS One"},{"issue":"1","key":"819_CR66","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/dvdy.20603","volume":"235","author":"TA Franz-Odendaal","year":"2006","unstructured":"Franz-Odendaal TA, Hall BK, Witten PE (2006) Buried alive: how osteoblasts become osteocytes. Dev Dyn 235(1):176\u2013190","journal-title":"Dev Dyn"},{"issue":"10","key":"819_CR67","doi-asserted-by":"publisher","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6(10):e25900","journal-title":"PLoS One"},{"key":"819_CR68","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone. 96:29\u201337","journal-title":"Bone."},{"issue":"1","key":"819_CR69","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10695-018-0568-z","volume":"45","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen B, Yan Y, Zhu GX (2019) Hepcidin protects against iron overload-induced inhibition of bone formation in zebrafish. Fish Physiol Biochem 45(1):365\u2013374","journal-title":"Fish Physiol Biochem"},{"issue":"3","key":"819_CR70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00223-013-9817-4","volume":"94","author":"B Chen","year":"2014","unstructured":"Chen B, Yan YL, Liu C, Bo L, Li GF, Wang H et al (2014) Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model. Calcif Tissue Int 94(3):353\u2013360","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"819_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2016.05.118","volume":"476","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Yan Y, Wang X, Zhu G, Xu YJ (2016) Hepcidin inhibition on the effect of osteogenesis in zebrafish. Biochem Biophys Res Commun 476(1):1\u20136","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"819_CR72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10534-018-0133-3","volume":"31","author":"Y Li","year":"2018","unstructured":"Li Y, Bai B, Zhang Y (2018) Expression of iron-regulators in the bone tissue of rats with and without iron overload. Biometals. 31(5):749\u2013757","journal-title":"Biometals."},{"key":"819_CR73","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bone.2016.09.023","volume":"94","author":"Z Xu","year":"2017","unstructured":"Xu Z, Sun W, Li Y, Ling S, Zhao C, Zhong G et al (2017) The regulation of iron metabolism by hepcidin contributes to unloading-induced bone loss. Bone. 94:152\u2013161","journal-title":"Bone."},{"issue":"1","key":"819_CR74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3892\/br.2012.6","volume":"1","author":"J Li","year":"2013","unstructured":"Li J, Hou Y, Zhang S, Ji H, Rong H, Qu G, Liu S (2013) Excess iron undermined bone load-bearing capacity through tumor necrosis factor-alpha-dependent osteoclastic activation in mice. Biomed Rep 1(1):85\u201388","journal-title":"Biomed Rep"},{"key":"819_CR75","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/B978-0-12-415784-2.00011-7","volume-title":"Translational endocrinology of bone","author":"F Oury","year":"2013","unstructured":"Oury F (2013) Chapter 11 - From gonads to bone, and back. In: Karsenty G (ed) Translational endocrinology of bone. Academic Press, San Diego, pp 123\u2013135"},{"issue":"11","key":"819_CR76","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/jbmr.1692","volume":"27","author":"BJ Kim","year":"2012","unstructured":"Kim BJ, Ahn SH, Bae SJ, Kim EH, Lee SH, Kim HK, Choe JW, Koh JM, Kim GS (2012) Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3-year retrospective longitudinal study. J Bone Miner Res 27(11):2279\u20132290","journal-title":"J Bone Miner Res"},{"issue":"2","key":"819_CR77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.pedneo.2016.08.012","volume":"59","author":"ES Abd El-Moneim","year":"2018","unstructured":"Abd El-Moneim ES, Zolaly MA, Al-Hawsawi ZM, Abdelmoneim AA, Abosdera MM (2018) Age-related changes in biochemical bone profile in thalassemic children. Pediatr Neonatol 59(2):189\u2013197","journal-title":"Pediatr Neonatol"},{"issue":"7","key":"819_CR78","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/08880010701533611","volume":"24","author":"NG Angelopoulos","year":"2007","unstructured":"Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Konstandelou E, Tolis G (2007) Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. Pediatr Hematol Oncol 24(7):481\u2013491","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"819_CR79","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00774-015-0689-8","volume":"34","author":"N Morabito","year":"2016","unstructured":"Morabito N, Catalano A, Gaudio A, Morini E, Bruno LM, Basile G et al (2016) Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis. J Bone Miner Metab 34(5):540\u2013546","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"819_CR80","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1515\/JPEM.2006.19.11.1335","volume":"19","author":"L Pratelli","year":"2006","unstructured":"Pratelli L, Verri E, Fortini M, Marconi S, Zolezzi C, Fornasari PM, Gamberini MR, de Sanctis V (2006) Chelation therapy and bone metabolism markers in thalassemia major. J Pediatr Endocrinol Metab 19(11):1335\u20131342","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9","key":"819_CR81","first-page":"1193","volume":"91","author":"E Voskaridou","year":"2006","unstructured":"Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 91(9):1193\u20131202","journal-title":"Haematologica."},{"issue":"12","key":"819_CR82","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1055\/s-0032-1312618","volume":"44","author":"E Voskaridou","year":"2012","unstructured":"Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V et al (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909\u2013913","journal-title":"Horm Metab Res"},{"issue":"6","key":"819_CR83","first-page":"813","volume":"91","author":"E Voskaridou","year":"2006","unstructured":"Voskaridou E, Stoupa E, Antoniadou L, Premetis E, Konstantopoulos K, Papassotiriou I et al (2006) Osteoporosis and osteosclerosis in sickle cell\/beta-thalassemia: the role of the RANKL\/osteoprotegerin axis. Haematologica. 91(6):813\u2013816","journal-title":"Haematologica."},{"issue":"4","key":"819_CR84","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1600-0609.2004.00395.x","volume":"74","author":"E Voskaridou","year":"2005","unstructured":"Voskaridou E, Terpos E (2005) Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur J Haematol 74(4):359\u2013361","journal-title":"Eur J Haematol"},{"issue":"4","key":"819_CR85","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1046\/j.1365-2141.2003.04657.x","volume":"123","author":"E Voskaridou","year":"2003","unstructured":"Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123(4):730\u2013737","journal-title":"Br J Haematol"},{"issue":"5","key":"819_CR86","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3324\/haematol.2008.000893","volume":"94","author":"E Voskaridou","year":"2009","unstructured":"Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica. 94(5):725\u2013728","journal-title":"Haematologica."},{"issue":"4","key":"819_CR87","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/BF03344015","volume":"25","author":"A Lasco","year":"2002","unstructured":"Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G et al (2002) Osteoporosis and beta-thalassemia major: role of the IGF-I\/IGFBP-III axis. J Endocrinol Investig 25(4):338\u2013344","journal-title":"J Endocrinol Investig"},{"issue":"10","key":"819_CR88","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","volume":"36","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M, Branco J, Brandi ML, Bruyere O, Chapurlat R, Cooper C et al (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther 36(10):2811\u20132824","journal-title":"Adv Ther"},{"issue":"3","key":"819_CR89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/10245330600702851","volume":"11","author":"OS Salama","year":"2006","unstructured":"Salama OS, Al-Tonbary YA, Shahin RA, Eldeen OA (2006) Unbalanced bone turnover in children with beta-thalassemia. Hematology. 11(3):197\u2013202","journal-title":"Hematology."},{"issue":"8","key":"819_CR90","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1210\/jc.2002-021548","volume":"88","author":"P Mahachoklertwattana","year":"2003","unstructured":"Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 88(8):3966\u20133972","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"819_CR91","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1359\/jbmr.2003.18.9.1682","volume":"18","author":"S Domrongkitchaiporn","year":"2003","unstructured":"Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, Kanokkantapong C, Rajatanavin R (2003) Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 18(9):1682\u20131688","journal-title":"J Bone Miner Res"},{"issue":"3","key":"819_CR92","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/EJE-15-0118","volume":"173","author":"F Mirza","year":"2015","unstructured":"Mirza F, Canalis E (2015) Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 173(3):R131\u2013R151","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"819_CR93","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00277-010-1007-0","volume":"89","author":"M Baldini","year":"2010","unstructured":"Baldini M, Forti S, Marcon A, Ulivieri FM, Orsatti A, Tampieri B, Airaghi L, Zanaboni L, Cappellini MD (2010) Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 89(12):1207\u20131213","journal-title":"Ann Hematol"},{"issue":"3","key":"819_CR94","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/2042018816641351","volume":"7","author":"G Handzlik-Orlik","year":"2016","unstructured":"Handzlik-Orlik G, Holecki M, Wilczynski K, Dulawa J (2016) Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab 7(3):128\u2013135","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"819_CR95","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00277-017-2959-0","volume":"96","author":"M Baldini","year":"2017","unstructured":"Baldini M, Marcon A, Ulivieri FM, Seghezzi S, Cassin R, Messina C et al (2017) Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables. Ann Hematol 96(6):995\u20131003","journal-title":"Ann Hematol"},{"issue":"10","key":"819_CR96","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","volume":"115","author":"AT Taher","year":"2010","unstructured":"Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S et al (2010) Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 115(10):1886\u20131892","journal-title":"Blood."},{"issue":"5","key":"819_CR97","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00277-016-2633-y","volume":"95","author":"M Poggi","year":"2016","unstructured":"Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, Terlizzi F, Guitarrini MR, Monti S, Maffei L, Losardo A, Pasin M, Toscano V (2016) Longitudinal changes of endocrine and bone disease in adults with beta-thalassemia major receiving different iron chelators over 5 years. Ann Hematol 95(5):757\u2013763","journal-title":"Ann Hematol"},{"issue":"11","key":"819_CR98","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/17474086.2019.1662721","volume":"12","author":"M Bordbar","year":"2019","unstructured":"Bordbar M, Haghpanah S, Zekavat OR, Saki F, Bazrafshan A, Bozorgi H (2019) Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients. Expert Rev Hematol 12(11):997\u20131003","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"819_CR99","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/BF03343738","volume":"23","author":"A Sartorio","year":"2000","unstructured":"Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P, Faglia G (2000) Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. J Endocrinol Investig 23(6):356\u2013361","journal-title":"J Endocrinol Investig"},{"issue":"6","key":"819_CR100","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1203\/00006450-196711000-00007","volume":"1","author":"FE Johnston","year":"1967","unstructured":"Johnston FE, Roseman JM (1967) The effects of more frequent transfusions upon bone loss in thalassemia major. Pediatr Res 1(6):479\u2013483","journal-title":"Pediatr Res"},{"issue":"5","key":"819_CR101","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/MPH.0b013e3182431ddb","volume":"34","author":"A Doulgeraki","year":"2012","unstructured":"Doulgeraki A, Athanasopoulou H, Voskaki I, Tzagaraki A, Karabatsos F, Fragodimitri C et al (2012) Bone health evaluation of children and adolescents with homozygous beta-thalassemia: implications for practice. J Pediatr Hematol Oncol 34(5):344\u2013348","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7998","key":"819_CR102","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(76)92035-3","volume":"2","author":"MA Hussain","year":"1976","unstructured":"Hussain MA, Green N, Flynn DM, Hussein S, Hoffbrand AV (1976) Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet. 2(7998):1278\u20131280","journal-title":"Lancet."},{"issue":"8","key":"819_CR103","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1056\/NEJM197708252970804","volume":"297","author":"RD Propper","year":"1977","unstructured":"Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF et al (1977) Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 297(8):418\u2013423","journal-title":"N Engl J Med"},{"issue":"12","key":"819_CR104","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1517\/14728220802517901","volume":"8","author":"S Dodd","year":"2008","unstructured":"Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (2008) N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 8(12):1955\u20131962","journal-title":"Expert Opin Biol Ther"},{"key":"819_CR105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5344\/ajev.1992.43.1.49","volume":"43","author":"EH Siemann","year":"1992","unstructured":"Siemann EH, Creasy LL (1992) Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43:49\u201352","journal-title":"Am J Enol Vitic"},{"issue":"4","key":"819_CR106","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.bbrc.2003.08.105","volume":"309","author":"SS Leonard","year":"2003","unstructured":"Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK et al (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309(4):1017\u20131026","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"819_CR107","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/sj.bjp.0701784","volume":"123","author":"S Rotondo","year":"1998","unstructured":"Rotondo S, Rajtar G, Manarini S, Celardo A, Rotillo D, de Gaetano G et al (1998) Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol 123(8):1691\u20131699","journal-title":"Br J Pharmacol"},{"issue":"12","key":"819_CR108","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/bph.13492","volume":"174","author":"N Xia","year":"2017","unstructured":"Xia N, Daiber A, Forstermann U, Li H (2017) Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol 174(12):1633\u20131646","journal-title":"Br J Pharmacol"},{"issue":"2","key":"819_CR109","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1600-079X.2005.00261.x","volume":"39","author":"RJ Reiter","year":"2005","unstructured":"Reiter RJ, Tan DX, Maldonado MD (2005) Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 39(2):215\u2013216","journal-title":"J Pineal Res"},{"issue":"3","key":"819_CR110","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jpi.12360","volume":"61","author":"RJ Reiter","year":"2016","unstructured":"Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L (2016) Melatonin as an antioxidant: under promises but over delivers. J Pineal Res 61(3):253\u2013278","journal-title":"J Pineal Res"},{"issue":"22","key":"819_CR111","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa073275","volume":"357","author":"JB Bussel","year":"2007","unstructured":"Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357(22):2237\u20132247","journal-title":"N Engl J Med"},{"issue":"9664","key":"819_CR112","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","volume":"373","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 373(9664):641\u2013648","journal-title":"Lancet."},{"issue":"6","key":"819_CR113","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.1002\/ajh.24705","volume":"92","author":"MP Lambert","year":"2017","unstructured":"Lambert MP, Witmer CM, Kwiatkowski JL (2017) Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Am J Hematol 92(6):E88\u2013E91","journal-title":"Am J Hematol"},{"issue":"17","key":"819_CR114","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","volume":"130","author":"E Vlachodimitropoulou","year":"2017","unstructured":"Vlachodimitropoulou E, Chen YL, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M, Cooper N, Hider R, Porter J (2017) Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood. 130(17):1923\u20131933","journal-title":"Blood."},{"issue":"11","key":"819_CR115","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1074\/jbc.M008923200","volume":"276","author":"C Pigeon","year":"2001","unstructured":"Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Lor\u00e9al O (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276(11):7811\u20137819","journal-title":"J Biol Chem"},{"issue":"2","key":"819_CR116","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1586\/17474086.2016.1124757","volume":"9","author":"NL Blanchette","year":"2016","unstructured":"Blanchette NL, Manz DH, Torti FM, Torti SV (2016) Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol 9(2):169\u2013186","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"819_CR117","doi-asserted-by":"publisher","first-page":"e0185236","DOI":"10.1371\/journal.pone.0185236","volume":"12","author":"K Zainabadi","year":"2017","unstructured":"Zainabadi K, Liu CJ, Caldwell ALM, Guarente L (2017) SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. PLoS One 12(9):e0185236","journal-title":"PLoS One"},{"key":"819_CR118","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.phrs.2019.03.007","volume":"143","author":"K Zainabadi","year":"2019","unstructured":"Zainabadi K (2019) Drugs targeting SIRT1, a new generation of therapeutics for osteoporosis and other bone related disorders? Pharmacol Res 143:97\u2013105","journal-title":"Pharmacol Res"},{"issue":"1","key":"819_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-017-0004-5","volume":"6","author":"J Chen","year":"2018","unstructured":"Chen J, Long F (2018) mTOR signaling in skeletal development and disease. Bone Res 6(1):1","journal-title":"Bone Res"},{"issue":"3","key":"819_CR120","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00198-015-3325-5","volume":"27","author":"D Luo","year":"2016","unstructured":"Luo D, Ren H, Li T, Lian K, Lin D (2016) Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy. Osteoporos Int 27(3):1093\u20131101","journal-title":"Osteoporos Int"},{"issue":"5","key":"819_CR121","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update Executive Summary. Endocr Pract 26(5):564\u2013570","journal-title":"Endocr Pract"},{"issue":"5","key":"819_CR122","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"819_CR123","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344","journal-title":"Osteoporos Int"},{"issue":"1","key":"819_CR124","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/nyas.13041","volume":"1368","author":"A Giusti","year":"2016","unstructured":"Giusti A, Pinto V, Forni GL, Pilotto A (2016) Management of beta-thalassemia-associated osteoporosis. Ann N Y Acad Sci 1368(1):73\u201381","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"819_CR125","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s42000-018-0019-3","volume":"17","author":"AN Tsartsalis","year":"2018","unstructured":"Tsartsalis AN, Lambrou GI, Tsartsalis D, Savvidis C, Karantza M, Terpos E et al (2018) The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis. Hormones (Athens) 17(2):153\u2013166","journal-title":"Hormones (Athens)"},{"key":"819_CR126","unstructured":"Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V (eds) (2014). Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd edn. Thalassaemia International Federation. Retrieved from https:\/\/www.thalassaemia.org.cy\/publications\/tif-publications\/guidelines-for-the-management-oftransfusion-dependent-thalassaemia-3rd-edition-2014\/"},{"issue":"8","key":"819_CR127","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s001980200087","volume":"13","author":"N Morabito","year":"2002","unstructured":"Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A et al (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13(8):644\u2013649","journal-title":"Osteoporos Int"},{"issue":"2","key":"819_CR128","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","volume":"158","author":"GL Forni","year":"2012","unstructured":"Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, D'Ascola DG, Borgna Pignatti C, Rigano P, Filosa A, Iolascon G, Nobili B, Baldini M, Rosa A, Pinto V, Palummeri E (2012) Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol 158(2):274\u2013282","journal-title":"Br J Haematol"},{"issue":"4","key":"819_CR129","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjh.12048","volume":"159","author":"R Chatterjee","year":"2012","unstructured":"Chatterjee R, Shah FT, Davis BA, Byers M, Sooranna D, Bajoria R, Pringle J, Porter JB (2012) Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in beta-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 159(4):462\u2013471","journal-title":"Br J Haematol"},{"issue":"1","key":"819_CR130","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11914-012-0129-9","volume":"11","author":"C Ro","year":"2013","unstructured":"Ro C, Cooper O (2013) Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep 11(1):45\u201351","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"819_CR131","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272\u20132282","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"819_CR132","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/bloodadvances.2018023085","volume":"2","author":"E Voskaridou","year":"2018","unstructured":"Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, Christoulas D, Dimopoulou M, Repa K, Papatheodorou A, Peppa M, Terpos E (2018) Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv 2(21):2837\u20132847","journal-title":"Blood Adv"},{"issue":"18","key":"819_CR133","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2165\/0003495-200868180-00012","volume":"68","author":"SK Blick","year":"2008","unstructured":"Blick SK, Dhillon S, Keam SJ (2008) Teriparatide: a review of its use in osteoporosis. Drugs. 68(18):2709\u20132737","journal-title":"Drugs."},{"issue":"12","key":"819_CR134","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/trf.13237","volume":"55","author":"S Tournis","year":"2015","unstructured":"Tournis S, Dede AD, Savvidis C, Triantafyllopoulos IK, Kattamis A, Papaioannou N (2015) Effects of teriparatide retreatment in a patient with beta-thalassemia major. Transfusion. 55(12):2905\u20132910","journal-title":"Transfusion."},{"issue":"2","key":"819_CR135","first-page":"119","volume":"62","author":"A Trotta","year":"2010","unstructured":"Trotta A, Corrado A, Cantatore FP (2010) Anabolic therapy of induced osteoporosis in beta-thalassaemia major: case report and literature review. Reumatismo. 62(2):119\u2013126","journal-title":"Reumatismo."},{"issue":"1","key":"819_CR136","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/16078454.2019.1570617","volume":"24","author":"E Voskaridou","year":"2019","unstructured":"Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Sonnleitner L, Papaefstathiou A, Dimopoulou M, Missbichler A, Kanellias N, Repa K, Papatheodorou A, Peppa M, Hawa G, Terpos E (2019) Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. Hematology. 24(1):318\u2013324","journal-title":"Hematology."},{"issue":"10","key":"819_CR137","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.1002\/ajh.23305","volume":"87","author":"EB Fung","year":"2012","unstructured":"Fung EB, Gariepy CA, Sawyer AJ, Higa A, Vichinsky EP (2012) The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study. Am J Hematol 87(10):E76\u2013E79","journal-title":"Am J Hematol"},{"issue":"7","key":"819_CR138","first-page":"4337","volume":"11","author":"L Chen","year":"2019","unstructured":"Chen L, Wang G, Wang Q, Liu Q, Sun Q, Chen L (2019) N-acetylcysteine prevents orchiectomy-induced osteoporosis by inhibiting oxidative stress and osteocyte senescence. Am J Transl Res 11(7):4337\u20134347","journal-title":"Am J Transl Res"},{"issue":"4","key":"819_CR139","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.trsl.2007.03.012","volume":"150","author":"KM Sanders","year":"2007","unstructured":"Sanders KM, Kotowicz MA, Nicholson GC (2007) Potential role of the antioxidant N-acetylcysteine in slowing bone resorption in early post-menopausal women: a pilot study. Transl Res 150(4):215","journal-title":"Transl Res"},{"issue":"10","key":"819_CR140","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/ajh.23786","volume":"89","author":"X Zhang","year":"2014","unstructured":"Zhang X, Camprecios G, Rimmele P, Liang R, Yalcin S, Mungamuri SK et al (2014) FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. Am J Hematol 89(10):954\u2013963","journal-title":"Am J Hematol"},{"issue":"2","key":"819_CR141","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3324\/haematol.2013.090076","volume":"99","author":"SS Franco","year":"2014","unstructured":"Franco SS, De Falco L, Ghaffari S, Brugnara C, Sinclair DA, Matte A et al (2014) Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica. 99(2):267\u2013275","journal-title":"Haematologica."},{"issue":"10","key":"819_CR142","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00277-018-3392-8","volume":"97","author":"S Haghpanah","year":"2018","unstructured":"Haghpanah S, Zarei T, Eshghi P, Zekavat O, Bordbar M, Hoormand M et al (2018) Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Ann Hematol 97(10):1919\u20131924","journal-title":"Ann Hematol"},{"issue":"4","key":"819_CR143","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/03630269.2015.1036882","volume":"39","author":"A Pecoraro","year":"2015","unstructured":"Pecoraro A, Troia A, Calzolari R, Scazzone C, Rigano P, Martorana A, Sacco M, Maggio A, di Marzo R (2015) Efficacy of rapamycin as inducer of Hb F in primary erythroid cultures from sickle cell disease and beta-thalassemia patients. Hemoglobin. 39(4):225\u2013229","journal-title":"Hemoglobin."}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-00819-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-020-00819-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-00819-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T08:57:31Z","timestamp":1696669051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-020-00819-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s11657-020-00819-z","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"143"}}